[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Northern Jiangsu People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":560},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,50,69,92,111,129,157,178,194,222,246,266,288,311,329,354,377,399,424,443,460,476,499,520,539],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100640414","effect-of-lsd-on-renal-function-in-cirrhosis-patients-with-portal-hypertension-bleeding-2-year-follow-up-100640414",false,"NCT07585786","Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Renal Function in Patients With Liver Cirrhosis, Portal Hypertension Bleeding","LSD-RFPH","Inclusion Criteria:\n\n1. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n2. Splenomegaly and hypersplenism\n3. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n4. Age 18-80 years, male or female\n5. Child-Pugh Class A or B liver function\n6. No history of primary renal disease or acute kidney injury (AKI)\n7. Signed written informed consent\n8. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)\n3. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection\n4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n5. Hepatic encephalopathy or refractory ascites within 1 month before surgery\n6. Pregnancy or lactation\n7. Poor compliance, inability to complete follow-up","ALL","18 Years","80 Years",{"count":21,"type":22},30,"ESTIMATED","2 Years","OBSERVATIONAL","Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .",[27,28,29,30],"Cirrhosis, Liver","Splenectomy; Status","Renal Function Abnormal","Portal Hypertension",[32,33,34,35,36,37],"Cirrhosis","Splenectomy","Laparoscopy","azygoportal disconnection","Renal function","Portal hypertension bleeding","NOT_YET_RECRUITING","2026-05-14",{"date":41,"type":42},"2026-05-18","ACTUAL",{"date":44,"type":22},"2026-05-01",{"date":46,"type":22},"2029-02-28",{"name":48,"class":49},"Northern Jiangsu People's Hospital","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":58,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":67,"locationsCount":68},"100639931","effect-of-laparoscopic-splenectomy-on-renal-function-in-cirrhotic-patients-with-hypersplenism-2-year-follow-up-100639931","NCT07585773","Effect of Laparoscopic Splenectomy on Renal Function in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Short-Term and Long-Term (2-Year) Effects of Laparoscopic Splenectomy on Renal Function in Patients With Liver Cirrhosis, Splenomegaly and Hypersplenism","LS-RF","Inclusion Criteria:\n\n1. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n2. Splenomegaly and hypersplenism\n3. No history of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n4. Age 18-80 years, male or female\n5. Child-Pugh Class A or B liver function\n6. No history of primary renal disease or acute kidney injury (AKI)\n7. Signed written informed consent\n8. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)\n3. Previous abdominal surgery precluding safe laparoscopic splenectomy\n4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n5. Cirrhotic complications (portal hypertension bleeding, hepatic encephalopathy, refractory ascites) within 1 month before surgery\n6. Pregnancy or lactation\n7. Poor compliance, inability to complete follow-up",{"count":21,"type":22},"Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether laparoscopic splenectomy can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .",[32,28,61,62],"Hypersplenism","Kidney Function Issue",[32,30,33,34,61],{"date":41,"type":42},{"date":44,"type":22},{"date":46,"type":22},{"name":48,"class":49},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":68},"100630648","long-term-efficacy-and-safety-of-lsd-versus-tips-for-cirrhotic-portal-hypertension-bleeding-and-hypersplenism-100630648","NCT07490405","Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism","Long-term Efficacy and Safety of Laparoscopic Splenectomy and Azygoportal Disconnection Versus Transjugular Intrahepatic Portosystemic Shunt for Cirrhotic Portal Hypertension With Acute Esophagogastric Variceal Bleeding and Hypersplenism","LSD、TIPS","Inclusion Criteria:\n\n1. Confirmed diagnosis of cirrhotic portal hypertension.\n2. Endoscopic examination confirmed the presence of severe esophagogastric varices accompanied by acute bleeding. Rebleeding occurred after endoscopic variceal ligation (EVL) treatment..\n3. Presence of hypersplenism causing significant thrombocytopenia and\u002For leukopenia.\n4. Liver function Child-Pugh class A or B (score 7-9).\n5. Age 18-75 years.\n6. Patient provides written informed consent.\n\nExclusion Criteria:\n\n1. Liver function Child-Pugh class C (score ≥10), or Model for End-Stage Liver Disease (MELD) score \\>18.\n2. Severe right heart failure or pulmonary hypertension.\n3. Uncontrolled systemic infection or sepsis.\n4. Polycystic liver disease, portal cavernous transformation, or portal vein thrombosis (affecting procedure or shunt creation).\n5. Advanced hepatocellular carcinoma (beyond Milan criteria) or other uncontrolled malignancies.\n6. Severe hepatic encephalopathy (West-Haven grade III-IV) unresponsive to medication.\n7. Severe contrast agent allergy (affecting TIPS procedure).\n8. Pregnancy or lactation.\n9. Any severe non-hepatic disease with a life expectancy \\\u003C1 year.\n10. Recent gastric and duodenal ulcers.\n11. Inability to comply with follow-up or provide informed consent.","75 Years",{"count":79,"type":22},140,"This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular intrahepatic portosystemic shunt (TIPS). It is a single-center, prospective trial. The primary outcome is the incidence of post-procedure hepatic encephalopathy. Secondary outcomes include changes in hepatic venous pressure gradient, portal and hepatic artery hemodynamics, liver function, renal function, complete blood count, immune function, hepatic reserve capacity, serological markers of liver fibrosis, re-bleeding rate, hepatocellular carcinoma incidence, recompensation incidence, overall survival, and bleeding-free survival. The study will provide high-level evidence for optimal treatment selection in this patient population.",[82],"Liver Cirrhosis",[82,84,85],"LSD","TIPS",{"date":41,"type":42},{"date":88,"type":22},"2026-06-01",{"date":90,"type":22},"2036-04-01",{"name":48,"class":49},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":100,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":110,"locationsCount":68},"100639930","effect-of-laparoscopic-splenectomy-on-lipid-profiles-in-cirrhotic-patients-with-hypersplenism-2-year-follow-up-100639930","NCT07588373","Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Short-Term and Long-Term (2-Year) Effects of Laparoscopic Splenectomy on Lipid Profiles in Patients With Liver Cirrhosis, Splenomegaly and Hypersplenism","LS-LP-CH","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n3. Splenomegaly and hypersplenism\n4. Child-Pugh Class A or B liver function\n5. Signed written informed consent\n6. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. No history of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n3. Previous abdominal surgery precluding safe laparoscopic splenectomy.\n4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n5. Metabolic\u002Fendocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.\n6. Infections\u002Finflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases.\n7. Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery\n8. Pregnancy or lactation\n9. Poor compliance, inability to complete follow-up",{"count":21,"type":22},"Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing laparoscopic splenectomy to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether laparoscopic splenectomy can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.",[32,28,61,103],"Lipid Profiles",[32,33,34,103,61,105],"portal hypertension","2026-05-10",{"date":39,"type":42},{"date":44,"type":22},{"date":46,"type":22},{"name":48,"class":49},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":119,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":128,"locationsCount":68},"100638416","effect-of-lsd-on-lipid-profiles-in-cirrhosis-patients-with-portal-hypertension-bleeding-2-year-follow-up-100638416","NCT07588334","Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Lipid Profiles in Patients With Liver Cirrhosis, Portal Hypertension Bleeding.","LSD-LPPH","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n3. Splenomegaly and hypersplenism\n4. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n5. Child-Pugh Class A or B liver function\n6. Signed written informed consent\n7. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection\n3. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n4. Metabolic\u002Fendocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.\n5. Infections\u002Finflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases.\n6. Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery\n7. Pregnancy or lactation\n8. Poor compliance, inability to complete follow-up",{"count":21,"type":22},"Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.",[27,28,30,103],[32,33,34,103,35,123,124],"Portal Hypertension Bleeding","hypersplenism",{"date":39,"type":42},{"date":44,"type":22},{"date":46,"type":22},{"name":48,"class":49},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":138,"phases":139,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100628473","vagus-nerve-guided-laparoscopic-splenectomy-and-azygoportal-disconnection-100628473","NCT07462091","Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection","VNLSD","Inclusion Criteria:\n\n1. A clinical, radiological or histologic diagnosis of cirrhosis of any etiology\n2. Splenomegaly with secondary hypersplenism\n3. Bleeding portal hypertension\n4. No evidence of portal vein system thrombosis by ultrasound evaluation and angio-CT\n5. Informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Delayed gastric emptying\n2. Diarrhea\n3. Hepatocellular carcinoma or any other malignancy,\n4. Hypercoagulable state other than the liver disease related\n5. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.\n6. Child - Pugh C\n7. Recent peptic ulcer disease\n8. History of Hemorrhagic stroke\n9. Pregnancy.\n10. Uncontrolled Hypertension\n11. Human immunodeficiency virus (HIV) infection",{"count":137,"type":22},15,"INTERVENTIONAL",[140],"NA","This study aimed to evaluate the effectiveness and safety of vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection, and to assess its impact on postoperative digestive complications and quality of life.",[32,61,143],"Hypertension, Portal",[34,145,32,146,33],"Vagus nerve","Azygoportal disconnection","RECRUITING","2026-03-26",{"date":150,"type":42},"2026-04-01",{"date":152,"type":42},"2026-03-25",{"date":154,"type":22},"2027-03-31",{"name":48,"class":49},2,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":138,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":68},"100628431","efficacy-of-apixaban-in-the-treatment-of-portal-vein-thrombosis-occurring-more-than-one-year-after-ls-100628431","NCT07461545","Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After Laparoscopic Splenectomy","Inclusion Criteria:\n\n1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.\n2. Splenomegaly with secondary hypersplenism.\n3. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.\n4. Underwent laparoscopic splenectomy at our center.\n5. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.\n6. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3\n7. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.\n8. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12.\n9. Developed portal vein thrombosis after 12 months post-surgery.\n10. Provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hepatocellular carcinoma or any other malignancy.\n2. Hypercoagulable state other than the liver disease related.\n3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.\n4. Portal hypertension bleeding .\n5. Child - Pugh C\n6. Recent peptic ulcer disease\n7. History of Hemorrhagic stroke\n8. Pregnancy.\n9. Uncontrolled Hypertension\n10. Human immunodeficiency virus (HIV) infection",{"count":165,"type":22},20,[140],"The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.",[32,33,169,143],"Portal Vein Thrombosis",[32,169,30,171,33,34],"Apixaban",{"date":173,"type":42},"2026-03-31",{"date":150,"type":22},{"date":176,"type":22},"2027-09-30",{"name":48,"class":49},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":138,"phases":186,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":192,"leadSponsor":193,"locationsCount":68},"100628430","efficacy-of-apixaban-in-treating-portal-vein-thrombosis-occurring-more-than-one-year-after-lsd-100628430","NCT07461532","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After Laparoscopic Splenectomy and Azygoportal Disconnection","Inclusion Criteria:\n\n1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.\n2. Portal hypertension bleeding .\n3. Splenomegaly with secondary hypersplenism.\n4. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.\n5. Underwent laparoscopic splenectomy at our center.\n6. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.\n7. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3\n8. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.\n9. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12.\n10. Developed portal vein thrombosis after 12 months post-surgery.\n11. Provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hepatocellular carcinoma or any other malignancy.\n2. Hypercoagulable state other than the liver disease related.\n3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.\n4. Child - Pugh C\n5. Recent peptic ulcer disease\n6. History of Hemorrhagic stroke\n7. Pregnancy.\n8. Uncontrolled Hypertension\n9. Human immunodeficiency virus (HIV) infection",{"count":165,"type":22},[140],"The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.",[32,33,169,143],[32,169,30,171,33,34,61,146],{"date":173,"type":42},{"date":150,"type":22},{"date":176,"type":22},{"name":48,"class":49},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":138,"phases":204,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":68},"100622398","phase-4-hydrocortisone-and-fludrocortisone-for-the-treatment-of-septic-shock-100622398","NCT07383103","Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock","Initiation of Hydrocortisone and Fludrocortisone in Adult Patients With Septic Shock：A Prospective Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n(1)18≤Age≤90; (2)Diagnosis of septic shock within 12 h.\n\nExclusion Criteria:\n\nPatients meeting any of the following conditions will be excluded:\n\n1. Systemic corticosteroid therapy within the last 3 months before septic shock;\n2. High-dose steroid therapy;\n3. Immunosuppression;\n4. Pregnant;\n5. Known allergy to hydrocortisone or fludrocortisone;\n6. Presence of gastrointestinal bleeding, perforation, or other conditions requiring fasting;\n7. Anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician);\n8. Refusal of the attending staff or patient family;\n9. Current participation in another clinical trial.","90 Years",{"count":203,"type":22},336,[205],"PHASE4","The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.",[208],"Septic Shock",[210,211,212,213],"septic shock","hydrocortisone","fludrocortisone","mortality","2026-03-03",{"date":216,"type":42},"2026-03-04",{"date":218,"type":42},"2026-03-02",{"date":220,"type":22},"2028-12-31",{"name":48,"class":49},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":229,"targetDuration":231,"studyType":24,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":68},"100617912","correlation-between-advanced-glycation-end-products-and-gastric-motility-disorder-in-diabetes-gastroparesis-100617912","NCT07324785","Correlation Between Advanced Glycation End Products and Gastric Motility Disorder in Diabetes Gastroparesis","The Role and Mechanism of SphK1\u002FS1P\u002FFOXO1 Axis Regulating KATP Channel Mediated Gastric Smooth Muscle Dysfunction in Diabetes Gastroparesis","Inclusion Criteria for diabetes gastroparesis group:\n\n* Meet the diagnostic criteria for diabetes\n* Presence of symptoms (see assessment of Gastroparesis Cardinal Symptom Index)\n* Age range from 18 to 75 years old\n* Voluntarily participate and sign an informed consent form\n\nInclusion Criteria for control group:\n\n* No history of diabetes\n* No symptoms (see assessment of Gastroparesis Cardinal Symptom Index)\n* Age range from 18 to 75 years old\n* Voluntarily participate and sign an informed consent form\n\nExclusion Criteria for diabetes gastroparesis group and control group:\n\n* Currently taking prokinetic drugs, anticholinergic drugs, and dopamine drugs that may affect gastric motility\n* Has a history of gastrointestinal surgery\n* Pregnant or preparing to conceive\n* There are neurological disorders such as Parkinson's disease that affect gastrointestinal function\n* Outlet obstruction caused by organic lesions in the pylorus",{"count":230,"type":22},50,"2 Weeks","This study is a prospective observational study. The study will explore the correlation between advanced glycation end products and gastric motility disorder in diabetic gastroparesis（DGP) through the collection of blood and gastric tissue samples and relevant data of patients with DGP and control group patients without diabetes history and gastroparesis symptoms.",[234],"Diabetic Gastroparesis",[236,237],"Diabetic gastroparesis","Advanced glycation end products","2026-02-14",{"date":240,"type":42},"2026-02-17",{"date":242,"type":42},"2026-01-07",{"date":244,"type":22},"2027-05-31",{"name":48,"class":49},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":252,"targetDuration":4,"studyType":138,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":68},"100620086","the-efficacy-of-personalized-local-anesthetic-dosing-based-on-ultrasound-measured-nerve-cross-sectional-area-in-brachial-plexus-block-a-non-inferiority-randomized-controlled-trial-100620086","NCT07353047","The Efficacy of Personalized Local Anesthetic Dosing Based on Ultrasound-Measured Nerve Cross-Sectional Area in Brachial Plexus Block: a Non-Inferiority Randomized Controlled Trial.","Inclusion Criteria:\n\nAge 18-80 years old, proposed for elective unilateral upper extremity surgery; ASA grade I-III; Planned to undergo ultrasound-guided interscalene sulcus brachial plexus block; Normal preoperative respiratory function; No history of neck surgery; No use of drugs that affect nerve conduction or opioids within 30 days prior to surgery\n\nExclusion Criteria:\n\nLocal infection, coagulation dysfunction, neuropathy; Allergy to ropivacaine or amide local anesthetics; Severe hepatic and renal insufficiency; Pregnancy or lactation; Expected dosing required to exceed the maximum safe single safe dose of ropivacaine; Inability to cooperate with ultrasound measurements or nerve block operators.",{"count":253,"type":22},300,[140],"This is a prospective, randomized, assessor-blinded, three-arm, non-inferiority clinical trial. The study aims to compare the effectiveness and safety of an individualized dosing strategy for local anesthetic in brachial plexus blocks against two standard methods. The experimental intervention uses ultrasound to measure the cross-sectional area (CSA) of the brachial plexus nerves to calculate a patient-specific dose of 0.5% ropivacaine. This is compared to a standard weight-based dosing regimen (2.5 mg\u002Fkg) and dosing based on the anesthesiologist's clinical experience. A total of 350 adult patients scheduled for elective unilateral upper limb surgery will be randomly assigned to one of the three groups. The primary outcome is the success rate of the nerve block 30 minutes after administration. Secondary outcomes include assessments of diaphragmatic function, postoperative pain scores, the incidence of complications (such as nerve involvement or systemic toxicity), and patient satisfaction. The hypothesis is that the CSA-based dosing method will be non-inferior to the conventional methods in achieving successful anesthesia while potentially optimizing drug dosage.",[257],"Upper Limb Surgery","2026-01-13",{"date":260,"type":42},"2026-01-20",{"date":262,"type":22},"2026-02-01",{"date":264,"type":22},"2026-09-30",{"name":48,"class":49},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":138,"phases":275,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":68},"100596790","phase-2-tislelizumab-combined-with-thoracic-radiotherapy-as-neoadjuvant-therapy-for-resectable-nsclc-100596790","NCT07050056","Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC","Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC: A Single Arm, Phase II Clinical Study","Inclusion Criteria:\n\n* Fully understand the study and voluntarily sign the informed consent form (ICF);\n* Aged 18-70 years, regardless of gender;\n* Previously untreated, histologically confirmed resectable stage IB-IIIA NSCLC (AJCC 9th edition staging);\n* At least one measurable lesion per RECIST v1.1 criteria;\n* Willing to provide PD-L1 immunohistochemistry slides and corresponding pathology reports for biomarker evaluation;\n* Presence of lesions suitable for radiotherapy as assessed by the study team;\n* ECOG performance status of 0-1;\n* Adequate organ function;\n* Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures;\n* Sufficient pulmonary function to tolerate planned lung resection surgery, as assessed by a surgeon;\n* Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. Both female participants of childbearing potential and male participants with partners of childbearing potential must agree to use highly effective contraception during the study and for 180 days after the last dose of the study drug.\n\nExclusion Criteria:\n\n* Presence of locally advanced unresectable or metastatic disease;\n* NSCLC involving the superior sulcus, large cell neuroendocrine carcinoma (LCNEC), or sarcomatoid tumors;\n* Participants with known EGFR mutations or ALK translocations (non-squamous NSCLC subjects must have confirmed EGFR\u002FALK mutation status);\n* Prior systemic anticancer therapy for early-stage NSCLC, including investigational drugs; Contraindications to radiotherapy or inability to undergo radiotherapy;\n* History of (non-infectious) pneumonitis\u002Finterstitial lung disease requiring steroids or current pneumonitis\u002Finterstitial lung disease requiring steroid treatment;\n* Known active tuberculosis (TB) history; Known active infection requiring systemic therapy; Any known or suspected autoimmune disease or immunodeficiency;\n* Active hepatitis B infection; Administration of live vaccines within 30 days before the first dose;\n* Grade ≥2 peripheral neuropathy;\n* Prior treatment with PD-1\u002FPD-L1 inhibitors or drugs targeting other T-cell receptors (e.g., CTLA-4, OX-40, etc.);\n* History of severe hypersensitivity to monoclonal antibodies;\n* Severe or uncontrolled underlying medical conditions;\n* Any condition that, in the investigator's judgment, may confound study results, interfere with the subject's participation, or compromise the subject's best interest in the study.","70 Years",{"count":165,"type":22},[276],"PHASE2","This study aims to explore the efficacy and safety of radiotherapy combined with immunotherapy in the neoadjuvant treatment of resectable NSCLC.",[279],"Resectable NSCLC","2026-01-08",{"date":282,"type":42},"2026-01-09",{"date":284,"type":42},"2025-08-01",{"date":286,"type":22},"2027-12-31",{"name":48,"class":49},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":295,"targetDuration":4,"studyType":138,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":68},"100618884","phase-2-efcacy-and-safety-of-postoperative-adjuvant-hepatic-arterial-infusion-chemotherapy-with-mfolfox-in-hepatocellular-carcinoma-with-high-risk-recurrence-factors-100618884","NCT07337421","Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors","Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX(Modified Folinic Acid, Fluorouracil, and Oxaliplatin) in Hepatocellular Carcinoma With High-risk Recurrence Factors：A Single-center, Phase II, Single-arm, Prospective Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years.\n2. Histologically\u002Fcytologically confirmed hepatocellular carcinoma (HCC) (fibrotic HCC and mixed HCC\u002Fbiliary carcinoma subtypes were excluded from inclusion criteria), with no prior treatment for HCC (including but not limited to chemotherapy, targeted therapy, immunotherapy, cell therapy, local radiotherapy, and interventional therapy) before surgery.\n3. Patients who underwent radical surgery within the first 8 weeks and meet the following criteria: a. Histologically confirmed negative surgical margins (R0) for radical surgery: 1) No residual cancer on gross intraoperative or postoperative imaging; 2) Liver margins\\>1cm from tumor boundary, or margins ≤1cm with no tumor cell remnants in resected pathological tissue; b. Imaging examination (enhanced chest CT, abdominal CT or MRI, pelvic CT or MRI) performed ≥4 weeks after surgical resection or ablation to confirm complete radiological response.\n4. ECOG score ranges from 0 to 1.\n5. Patients meeting any of the following high-risk factors for hepatocellular carcinoma recurrence after radical surgery: 1) Single tumor\\>5 cm 2) Concurrent vascular invasion (microvascular invasion or major vessel invasion Vp1-2) 3) Multiple lesions with ≥3 tumors 4) Tumor grade Edmondson III-IV 5) Surgical margin ≤1cm\n6. For patients with preoperative AFP elevation, post-radical surgery or ablation, AFP levels must have significantly decreased and show no significant upward trend.\n7. Subjects with Hepatitis B or C Virus(HBV or HCV) infection must undergo standardized antiviral therapy prior to enrollment and continue the treatment during the study period.\n8. The patient must have adequate organ and bone marrow function, with laboratory test values meeting the following criteria: 1) Complete blood count (CBC): Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL; platelet count (PLT) ≥80×10⁹\u002FL; hemoglobin (Hb) ≥90 g\u002FL; 2) Liver function: Serum totalbilirubin (TBIL) ≤2×upper limit of normal (ULN), or direct bilirubin ≤ULN for subjects with TBIL\\>2×ULN; alanineaminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN; serum albumin ≥28 g\u002FL; 3) Renal function: Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance (CCr) ≥45 mL\u002Fmin (Cockcroft-Gault formula) for subjects with Cr\\>1.5×ULN; 4) Urinalysis shows urine protein \\\u003C2+; For subjects with baseline urinalysis showing proteinuria ≥2+ in routine urine tests, 24-hour urine collection should be performed with 24-hour urine protein quantification \\\u003C1g; 5) Coagulation function: International Normalized Ratio (INR) or Activated Partial Thromboplastin Time (APTT) ≤1.5×Upper Limit of Normal (ULN).\n9. Life expectancy exceeding 12 months.\n10. Not pregnant.\n\nExclusion Criteria:\n\n1. Presence of extrahepatic metastasis, residual lesions, or recurrence on imaging after surgery or ablation.\n2. Patients who have undergone adjuvant therapies such as transarterial chemoembolization (TACE) after radical surgery.\n3. Child-Pugh classification grade B or C, or a history of hepatic encephalopathy.\n4. Presence of clinically significant pericardial effusion; or clinical symptoms requiring drainage of pleural effusion or ascites.\n5. History of bleeding events within 6 months prior to enrollment, such as esophageal or gastric variceal bleeding caused by portal hypertension. Subjects with esophageal or gastric varices requiring intervention within 28 days before enrollment. Untreated or inadequately treated esophageal or gastric varices deemed by investigators to pose a high risk of bleeding.\n6. The subject is unable to undergo contrast-enhanced liver CT or MRI scans.\n7. Patients who do not meet the criteria for radical surgery.\n8. Received Chinese herbal medicine or Chinese patent medicine with antitumor indications or immunomodulatory drugs (including systemic use of thymosin, interferon, etc.) within 14 days prior to enrollment.\n9. Participation in other drug clinical trials within 4 weeks prior to enrollment.\n10. Co-infection with HBV and HCV (defined as HCV infection history with negative HCV RNA, which was considered as non-infection in this study).\n11. History of arterial or venous thromboembolic events occurring within 6 months prior to enrollment, including myocardial infarction (MI), unstable angina, cerebrovascular accident or transient ischemic attack (TIA), pulmonary embolism (PE), deep vein thrombosis (DVT), or any other severe thromboembolic event.\n12. Patients with cardiopulmonary insufficiency.\n13. Severe infection in the active phase or with poor clinical control. A severe infection within 4 weeks prior to the first treatment, including but not limited to hospitalization due to infection, bacteremia, or severe pneumonia complications.\n14. Known hypersensitivity to any investigational drug ingredients; or a history of severe allergic reactions to other traditional Chinese patent medicines.\n15. Known history of drug abuse, alcoholism, or substance use.\n16. Individuals with a history of psychiatric disorders and lacking capacity for conduct or having limited capacity for conduct.\n17. Other acute or chronic diseases, mental disorders, or abnormal laboratory test results that may lead to the following outcomes: increased risks for the subject to participate in the study or receive study treatment, interference with the interpretation of study results, or, at the investigator's discretion, that participation in the study is not in the subject's best interest.",{"count":21,"type":22},[276],"This is a single-center, single-arm, prospective trial to explore the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC) with mFOLFOX in hepatocellular carcinoma with high-risk recurrence factors.",[299],"Hepatocellular Carcinoma (HCC)",[301,302,303],"hepatocellular carcinoma","recurrence","postoperative adjuvant chemoinfusion","2026-01-04",{"date":258,"type":42},{"date":307,"type":42},"2025-09-01",{"date":309,"type":22},"2027-12-01",{"name":48,"class":49},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":317,"targetDuration":4,"studyType":138,"phases":318,"briefSummary":319,"conditions":320,"keywords":321,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":68},"100618887","phase-2-efficacy-and-safety-of-icaritin-combined-with-mfolfox-in-postoperative-hcc-with-high-risk-recurrence-factors-100618887","NCT07337460","Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors","Icaritin Soft Capsules Combined With Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in HCC With High-risk Recurrence Factors: A Single-center, Phase II, Single-arm, Prospective Study",{"count":21,"type":22},[276],"This is a single-center, single-arm, prospective trial to explore the efficacy and safety of Icaritin Soft Capsules combined with postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC) with Modified Folinic acid, Fluorouracil, and Oxaliplatin (mFOLFOX) in hepatocellular carcinoma (HCC) with high-risk recurrence factors.",[299],[322,303,302],"Hepatocellular Carcinoma",{"date":258,"type":42},{"date":325,"type":42},"2025-11-01",{"date":327,"type":22},"2028-01-31",{"name":48,"class":49},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":138,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":68},"100608739","laparoscopic-partial-splenectomy-for-hypersplenism-in-liver-cirrhosis-patients-100608739","NCT07205471","Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients","The Clinical Efficacy of Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients","LPSH","Inclusion Criteria:\n\n* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology\n* Splenomegaly with secondary hypersplenism\n* gastroesophageal variceal bleeding\n* Informed consent to participate in the study\n\nExclusion Criteria:\n\n* Hepatocellular carcinoma or any other malignancy,\n* Child-Pugh grade C\n* Recent peptic ulcer disease\n* History of Hemorrhagic stroke\n* Pregnancy.\n* Uncontrolled Hypertension\n* Human immunodeficiency virus (HIV) infection",{"count":21,"type":22},[140],"In this study,the researchers compared the changes in immune function-related indicators in patients with liver cirrhosis following laparoscopic partial splenectomy,to determine whether this surgical intervention can enhance postoperative immune function and thereby improve patient outcomes.",[341,28,342],"Cirrhoses, Liver","Partial",[32,33,34,344,345],"immune function","partial","2025-09-25",{"date":348,"type":42},"2025-10-03",{"date":350,"type":42},"2025-09-24",{"date":352,"type":22},"2028-09-24",{"name":48,"class":49},{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":138,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":68},"100472560","ct-guided-localization-for-micro-hepatocellular-carcinoma-before-surgical-resection-100472560","NCT05433467","CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection","The Feasibility of CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection","CTMH","Inclusion Criteria:\n\n1. Be at least 18 years old and give informed consent to participate in the study\n2. A preoperative (clinical, radiological, or histological) diagnosis of cirrhosis of the liver due to any cause.\n3. micro hepatocellular carcinoma (diameter less than 1cm).\n4. Preoperative CT plain scan could not find the lesion, and preoperative B-ultrasound could not find the lesion.\n5. Preoperative CT enhancement or MRI can detect the lesion.\n\nExclusion Criteria:\n\n1. Child-Pugh grade C\n2. Uncontrolled Hypertension\n3. Severe lung dysfunction\n4. Severe cardiac dysfunction",{"count":363,"type":22},5,[140],"In this project, the preoperative anatomical location of micro hepatocellular carcinoma under the guidance of CT can provide guidance for accurate surgical resection. It may also shorten the operation time and reduce intraoperative bleeding.",[27,322],[32,301,368],"localization needle","2025-08-07",{"date":371,"type":42},"2025-08-13",{"date":373,"type":42},"2022-05-01",{"date":375,"type":22},"2026-04-30",{"name":48,"class":49},{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":385,"targetDuration":4,"studyType":138,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":396,"leadSponsor":398,"locationsCount":68},"100598476","effect-of-thread-embedding-acupuncture-on-postoperative-ileus-recovery-after-colorectal-cancer-surgery-a-multicenter-randomized-controlled-trial-100598476","NCT07071987","Effect of Thread Embedding Acupuncture on Postoperative Ileus Recovery After Colorectal Cancer Surgery: A Multicenter Randomized Controlled Trial","A Multicenter, Randomized Controlled Trial to Evaluate the Efficacy of Thread Embedding Acupuncture in Reducing Postoperative Ileus After Colorectal Cancer Surgery","THREAD-POI","Inclusion Criteria:\n\nAge 18-80 years Diagnosed with stage I-III colorectal cancer Scheduled for elective laparoscopic colorectal resection ASA Physical Status I-III Ability to provide informed consent\n\nExclusion Criteria:\n\nHistory of prior major abdominal surgery Emergency or palliative surgery Combined organ resection or open conversion Severe postoperative complications (e.g., anastomotic leak, GI bleeding) Severe cardiac, hepatic, renal, or psychiatric comorbidities Refusal to undergo acupuncture",{"count":253,"type":22},[140],"This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of thread embedding acupuncture (TEA) in promoting gastrointestinal recovery after laparoscopic colorectal cancer surgery. The primary outcome is the time to first flatus. Secondary outcomes include time to first defecation, tolerance to oral intake, length of hospital stay, and patient-reported quality of life.",[389,390,391],"Colorectal Cancer","Postoperative Ileus","LARS - Low Anterior Resection Syndrome","2025-07-16",{"date":394,"type":42},"2025-07-18",{"date":284,"type":22},{"date":397,"type":22},"2027-07-31",{"name":48,"class":49},{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":138,"phases":407,"briefSummary":408,"conditions":409,"keywords":413,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":68},"100597062","clinical-study-on-laparoscopic-resection-of-splenic-artery-aneurysm-with-preservation-of-spleen-100597062","NCT07053605","Clinical Study on Laparoscopic Resection of Splenic Artery Aneurysm With Preservation of Spleen","Inclusion Criteria:\n\n* Asymptomatic splenic artery aneurysms with a diameter\\>2 cm,ruptured splenic artery aneurysms,and splenic artery aneurysms with a diameter increase\\>0.5 cm\u002Fyear.\n\nAneurysm located in the main trunk of the splenic artery. Informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with malignancies Hepatic cirrhosis with portal hypertension peptic ulcer disease Recent peptic ulcer disease History of Hemorrhagic stroke Pregnancy hematological diseases Uncontrolled Hypertension Human immunodeficiency virus (HIV) infection",{"count":406,"type":22},10,[140],"In this study, researchers examined the changes in related indicators such as immune function, splenic vein,proper hepatic artery, and portal venous hemodynamics following laparoscopic resection of a splenic artery aneurysm. We determined the changes in these patient-related indicators after surgical treatment and whether these changes could improve patient outcomes.",[410,411,412],"Splenic Artery Aneurysm","Immune Function","Hemodynamics",[34,414,415,412],"resection of splenic artery aneurysm","Immune function","2025-07-01",{"date":418,"type":42},"2025-07-08",{"date":420,"type":42},"2025-06-23",{"date":422,"type":22},"2027-06-30",{"name":48,"class":49},{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":429,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":138,"phases":431,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":68},"100465252","the-effect-of-laparoscopic-splenectomy-and-azygoportal-disconnection-on-the-immune-function-for-cirrhosis-patients-100465252","NCT05338294","The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients","ELSDI",{"count":165,"type":22},[140],"In this study, the investigators compared the improvement of immune function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative immune function and improve patient prognosis.",[27,28],[32,33,34,415,146],"2025-05-26",{"date":437,"type":42},"2025-05-28",{"date":439,"type":42},"2022-03-01",{"date":441,"type":22},"2025-07-31",{"name":48,"class":49},{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":448,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":138,"phases":450,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":459,"locationsCount":68},"100464264","the-effect-of-laparoscopic-splenectomy-and-azygoportal-disconnection-on-liver-reserve-function-for-cirrhosis-patients-100464264","NCT05325437","The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients","ELSDL",{"count":165,"type":22},[140],"In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative liver reserve function and improve patient prognosis.",[27,28,30],[32,33,146,34,454],"Liver Reserve Function",{"date":456,"type":42},"2025-05-30",{"date":439,"type":42},{"date":441,"type":22},{"name":48,"class":49},{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":138,"phases":468,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":475,"locationsCount":68},"100464263","the-effect-of-laparoscopic-splenectomy-on-liver-reserve-function-for-cirrhosis-patients-100464263","NCT05325424","The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients","ELSL","Inclusion Criteria:\n\n* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology\n* Splenomegaly with secondary hypersplenism, Platelet count \\\u003C 50\\*10\\^9\u002FL\n* Informed consent to participate in the study\n\nExclusion Criteria:\n\n* Hepatocellular carcinoma or any other malignancy,\n* Child-Pugh grade C\n* Recent peptic ulcer disease\n* History of Hemorrhagic stroke\n* Pregnancy.\n* Uncontrolled Hypertension\n* Bleeding portal hypertension\n* Human immunodeficiency virus (HIV) infection",{"count":165,"type":22},[140],"In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy. To determine whether surgical treatment can help enhance postoperative liver reserve function and improve patient prognosis.",[27,28],[32,33,454,34],{"date":456,"type":42},{"date":439,"type":42},{"date":441,"type":22},{"name":48,"class":49},{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":484,"minAge":4,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":138,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":4},"100583908","phase-2-a-study-of-ql1706-combined-with-nine-hpv-vaccine-as-first-line-treatment-for-persistent-recurrent-or-metastatic-cervical-cancer-100583908","NCT06882447","A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer","A Prospective, Single-center, Single-arm, Phase II Study of QL1706 Combined with Nine价HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer","QL1706","1. Patients with unsystematically treated cervical cancer, who voluntarily participate in the clinical study; fully understand and informed about the study and sign the Informed Consent Form (ICF); willing to follow and have the ability to complete all the trial procedures.\n2. With histologically confirmed diagnosis of cervical cancer, a pathology report and pathology slides are required.\n3. have at least one measurable lesion as assessed by the investigator according to RECIST 1.1.\n\n   Note: Measurable target lesions cannot be selected from previous radiotherapy sites. If the target lesion at the site of prior radiotherapy is the only optional target lesion, the investigator is required to provide anterior and posterior imaging data showing significant progression of this lesion.\n4. Recovery of AE associated with prior antitumor therapy to CTCAE ≤ Grade 1 (except for Grade 2 alopecia).\n5. ECOG score ≤ 1 within 7 days prior to first dose of study drug.\n6. expected survival ≥ 12 weeks.\n7. Subjects with chronic HBV infection must have HBV-DNA \\\u003C 1000 copies\u002Fml and must agree to receive antiviral therapy according to treatment guidelines for patients with hepatitis B surface antigen positivity; patients with HCV-RNA positivity must agree to receive antiviral therapy according to treatment guidelines and have liver function at CTCAE ≤ grade 1.\n8. Normal major organ function, i.e., the following criteria are met (no transfusion, erythropoietin, or colony-stimulating factor (G-CSF) therapy within 14 days prior to administration of study drug) Hematologic Neutrophils (ANC) ≥ 1.5 x 109\u002FL Platelets (PLT) ≥ 90×109\u002FL Hemoglobin (Hb) ≥ 90g\u002FL Liver Function Total bilirubin (TBIL) ≤ 1.5 x upper limit of normal (ULN) Glutamate aminotransferase (ALT) ≤ 2.5×ULN; For patients with liver metastases ≤ 5 × ULN Aspartate aminotransferase (AST) ≤ 2.5 × ULN; For patients with liver metastases ≤ 5×ULN Renal Function Creatinine (Cr) ≤ 1.5×ULN; If \\> 1.5 x ULN, creatinine clearance ≥ 50 ml\u002Fmin. (calculated according to the Cockcroft-Gault formula) Coagulation Activated partial thromboplastin time (APTT) ≤ 1.5 x ULN Prothrombin time (PT) ≤ 1.5×ULN International normalized ratio (INR) ≤ 1.5×ULN\n9. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to initiation of study drug and be willing to use a hi ghly effective method of contraception for the duration of the trial and for 90 days after the last administration of the test drug.","FEMALE",{"count":486,"type":22},35,[276],"The study medications were used as follows: 1 cycle every 21 days (3 weeks) of the following regimen.\n\nTest drug: QL1706, HPV 9-valent vaccine\n\nQL1706: Dose: 5 mg\u002Fkg ; intravenous infusion (ivgtt), administered on Day 1 of each cycle and every 3 weeks (21 days).\n\nTreatment will continue until loss of clinical benefit, occurrence of intolerable toxicity, patient or physician decision to discontinue treatment, death of the patient receiving the experimental treatment, or completion of 2 years of dosing (35 dosing cycles), withdrawal of informed consent by the subject, pregnancy of the subject, noncompliance with protocol or procedural requirements, or for administrative reasons.\n\nHPV 9-valent vaccine: 1st dose 1 day prior to first QL1706 administration; 2nd dose 2 months after 1st dose; 3rd dose 6 months after 1st dose.",[490],"Cervical Cancer Stage IVB","2025-03-24",{"date":493,"type":42},"2025-03-28",{"date":495,"type":22},"2025-03",{"date":497,"type":22},"2028-12",{"name":48,"class":49},{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":506,"targetDuration":4,"studyType":138,"phases":507,"briefSummary":508,"conditions":509,"keywords":511,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":519,"locationsCount":4},"100584103","phase-2-an-exploratory-clinical-study-on-neoadjuvant-treatment-of-hepatocellular-carcinoma-with-ql1706-combined-with-lenvatinib-100584103","NCT06884982","An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib","An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with Iparomlimab and Tuvonralimab Injection Combined with Lenvatinib","Inclusion Criteria:\n\n1. Age ≥18 years and ≤ 75 years；\n2. Confirmed by pathological or imaging diagnosis as CNLC Ib\u002FIIa\u002FIIb\u002FIIIa HCC (fibrotic plate and mixed hepatocellular\u002Fcholangiocarcinoma subtypes do not meet the inclusion criteria);\n3. Patients who have not received surgery or systemic treatment before enrollment and have experienced recurrence within 2 years after surgery can be included;\n4. MDT team determines that HCC with high-risk factors for recurrence (such as macroscopic cancer thrombus, multiple tumors, satellite nodules, tumor diameter \\> 5 cm, imaging vascular invasion or preoperative AFP \\> 200 U\u002Fml) is resectable;\n5. Positive hepatitis B surface antigen, no restrictions on anti-hepatitis B virus treatment;\n6. At least one measurable lesion based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) evaluated by the investigator;\n7. Organ function levels must meet the following requirements: i. Adequate bone marrow reserve: absolute neutrophil count \\>= 1.5 x 10\\^9\u002FL, white blood cell count \\>= 3 x 10\\^9\u002FL, platelet count \\>= 90 x 10\\^9\u002FL, and hemoglobin \\>= 9 g\u002FdL; ii. Liver: plasma albumin \\>= 2.8 g\u002FdL; for patients without liver metastasis, serum bilirubin \\\u003C= 2xULN, and for patients with liver metastasis, serum bilirubin \\\u003C= 3xULN; for patients without liver metastasis, AST and ALT \\\u003C= 2.5xULN, and for patients with liver metastasis, AST and ALT \\\u003C= 5xULN; iii. Kidney: serum creatinine \\\u003C= 1.5xULN; iv. Heart: left ventricular ejection fraction (LVEF) \\>= 50% (no blood transfusion, no use of hematopoietic growth factors and human albumin within 14 days before screening);\n8. Non-surgical sterilized female or male subjects of childbearing age, must agree to use a medically approved contraceptive method (such as intrauterine device, contraceptive pills or condoms) for contraception during the study treatment period and within 6 months after the end of the study treatment period; for non-surgical sterilized female subjects, the HCG test must be negative within 7 days before enrollment and must not be lactating;\n9. Child-Pugh: A\u002FB grade (\\\u003C= 7 points);\n10. ECOG performance status 0-1;\n11. Expected survival \\>= 6 months.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Patients with imaging evidence showing portal vein tumor thrombus reaching Vp3 or Vp4;\n3. Patients who have received PD-1 antibody, PD-L1 antibody, CTLA-4 antibody or lenvatinib before; those who participated in other clinical trials within 30 days before screening;\n4. Patients with active tuberculosis infection. Those who have active pulmonary tuberculosis within 1 year before enrollment; those who have had active tuberculosis infection for more than 1 year before enrollment and have not received regular anti-tuberculosis treatment or tuberculosis is still active;\n5. Patients with gastrointestinal malabsorption, gastrointestinal anastomosis or any other conditions that may affect the absorption of lenvatinib;\n6. Patients with NYHA II grade or above congestive heart failure history, unstable angina pectoris, myocardial infarction within 6 months or severe arrhythmia with significant cardiovascular damage within 6 months;\n7. Within 3 weeks before the first administration of the study drug, patients have experienced gastrointestinal bleeding events or active hemoptysis (at least 0.5 teaspoons of bright red blood);\n8. Patients with bleeding or thrombotic diseases or using X-factor inhibitors or anticoagulants that require monitoring of the international normalized ratio (INR), such as warfarin or similar drugs. Low molecular weight heparin treatment is allowed. Antiplatelet drugs at the treatment dose (such as aspirin ≥ 325 mg\u002Fd) are not allowed to be used during the study process;\n9. Patients who require immunosuppressive therapy after organ transplantation; patients who have received immunosuppressive drugs or systemic corticosteroids to achieve immunosuppression purposes within 14 days before enrollment (such as \\> 10 mg\u002Fday prednisone or equivalent drugs);\n10. Patients with active ulcers, unhealed wounds or fractures;\n11. Patients with hypertension and poor control of blood pressure (systolic blood pressure \\>= 140 mmHg or diastolic blood pressure \\>= 90 mmHg);\n12. Patients known to be allergic to any trial drug or excipients;\n13. Patients who have had other malignant tumors that have not been cured for more than 5 years, but do not include clearly cured malignant tumors, or curable cancers, such as basal cell carcinoma or squamous cell carcinoma of the skin, papillary thyroid carcinoma, localized low-risk prostate cancer, cervical carcinoma in situ or breast carcinoma in situ, etc.;\n14. Patients who have received allogeneic tissue\u002Forgan transplantation;\n15. Patients with known HIV infection history;\n16. According to the investigator's judgment, the subjects have other factors that may affect the trial results or cause the study to be forced to stop prematurely, such as alcohol abuse, drug abuse, other serious diseases (including mental diseases) that require combined treatment, severe laboratory test abnormalities, and factors affecting the patient's safety due to family or social factors.",{"count":21,"type":22},[276],"This is a single-center, single-arm, prospective trial to explore the efficacy and safety of neoadjuvant treatment with Iparomlimab and Tuvonralimab Injection combined with lenvatinib in patients with advanced HCC",[510],"HCC - Hepatocellular Carcinoma",[512],"neoadjuvant therapy","2025-03-13",{"date":515,"type":42},"2025-03-19",{"date":513,"type":22},{"date":518,"type":22},"2028-09-30",{"name":48,"class":49},{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":526,"targetDuration":4,"studyType":138,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":68},"100573043","a-pilot-study-of-the-effect-of-the-combination-of-inhaled-nitric-oxide-and-prone-position-under-eit-monitoring-on-efficacy-in-patients-with-ards-100573043","NCT06741137","A Pilot Study of the Effect of the Combination of Inhaled Nitric Oxide and Prone Position Under EIT Monitoring on Efficacy in Patients with ARDS","Inclusion Criteria:\n\n1. Age 18-80 years;\n2. Patients with moderate to severe ARDS on mechanical ventilation\n\nExclusion Criteria:\n\n1. Patients with severe asthma or acute exacerbation of chronic obstructive pulmonary disease (COPD), lung tumors, post-lung resection, and post-lung transplantation.\n2. Patients with hemodynamic instability requiring vasopressor support: dopamine or dobutamine \\>15 µg\u002Fkg\u002Fmin, norepinephrine \\>0.3 µg\u002Fkg\u002Fmin.\n3. Cardiogenic pulmonary edema.\n4. Patients with severe facial deformities, facial trauma, or severe thoracoabdominal trauma that precludes prone positioning ventilation.\n5. Mid to late pregnancy.\n6. Patients with a history of malignancy or other irreversible diseases\u002Fconditions, including those in the terminal stage.\n7. Patients expected to be discharged soon or requiring invasive mechanical ventilation for less than 24 hours.\n8. Patients currently participating in other studies.",{"count":21,"type":22},[140],"Investigating the Impact of Combined Inhaled Nitric Oxide and Prone Positioning on the Efficacy in ARDS Patients",[530],"ARDS","2025-01-08",{"date":533,"type":42},"2025-01-10",{"date":535,"type":42},"2024-01-01",{"date":537,"type":22},"2025-12-31",{"name":48,"class":49},{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":546,"targetDuration":4,"studyType":138,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":68},"100552598","preliminary-efficacy-analysis-of--double-tract-reconstruction-after-laparoscopic-proximal-gastrectomy-100552598","NCT06475170","Preliminary Efficacy Analysis of 'λ+α' Double-Tract Reconstruction After Laparoscopic Proximal Gastrectomy","Laparoscopic Proximal Gastrectomy With 'λ+α' Double-Tract Reconstruction for Upper-Third Early Gastric Cancer: A Randomized Clinical Trial.","Inclusion Criteria:\n\nAge between 18-75 years old, male or female; Pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1\u002F3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer： Ia and Ib (T1N0M0, T1N1M0, and T2N0M0) (14) according to the eighth edition of the AJCC (15); No distant metastasis was observed on preoperative chest radiograph, abdominal ultrasound, or upper abdominal CT; ASA grade 1-3; Patients without contraindications to surgery; Patients and their families voluntarily signed the informed consent form and participated in the study;\n\nExclusion Criteria:\n\nPatients diagnosed with primary tumors or distant metastasis; Patients whose tumor is located in the greater curvature side of the stomach; Patients with coagulation dysfunction that could not be corrected; Patients who were diagnosed with viral hepatitis and cirrhosis; Patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin; Patients with organ failure such as heart, lung, liver, brain, and kidney failure; Patients with ascites or cachexia preoperatively in poor general conditions; Patients diagnosed with immunodeficiency, immunosuppression, or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, SLE, etc.).\n\nPatients refusing to sign the informed consent of the study;",{"count":547,"type":22},60,[140],"The incidence of proximal gastric cancer has increased significantly in recent years. This may be due to weight gain, alcohol consumption, gastroesophageal reflux disease (GERD), and precancerous lesions. With a deeper understanding of the pattern of lymph node metastasis and the emergence of anti-reflux procedures, proximal gastrectomy has gradually received clinical attention. For early-stage upper gastric cancer and esophagogastric combination cancer cases that are expected to have a good prognosis, the ideal surgical procedure should be to preserve the distal stomach to improve the quality of life and to choose a reasonable digestive tract reconstruction method to prevent reflux. The anti-reflux effect of various proximal gastrectomy digestive tract reconstruction methods and the advantages and disadvantages of various surgical procedures are controversial, and the recognized ideal reconstruction method has not yet been established. Therefore, based on the stomach's anatomical features and the intercalated jejunum's anti-reflux mechanism, we propose a true dual-channel anastomosis for GI reconstruction, i.e., the \"λ+α dual-channel anastomosis\". This study aimed to investigate the efficacy and safety of proximal gastrectomy combined with \"λ+α double-channel anastomosis\" in the treatment of early gastric cancer.",[551,552],"Gastric Cancer","Reflux Esophagitis","2024-08-13",{"date":555,"type":42},"2024-08-15",{"date":557,"type":42},"2024-08-01",{"date":537,"type":22},{"name":48,"class":49},""]